Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IC19 CAR-T in Refractory Systemic Lupus Erythematosus
NCT06886919Phase 1Not yet recruiting
- Sponsor
- Immunochina Pharmaceuticals
- Start
- Mar 2025
- Primary completion
- Sep 2025
- Modality
- CAR-T Cells
01
Overview
Phase 1, open-label, single-arm trial of IC19 CAR-T in systemic lupus erythematosus (SLE), sponsored by Immunochina Pharmaceuticals. Primary endpoint: Safety of IC19 CAR-T cell therapy at 28 days. Planned start Mar 2025; status: not yet recruiting.
02
Drugs
IC19 CAR-T
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT06886919.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06886919.